Bio Sequence

Biosequence Assistant: Rapid Extraction and Localization of Sequence Information in Patents

26 September 2023
2 min read

Experience the New Features of the Patsnap Bio Sequence Database in September:

1) Sequence Assistant Optimization 

With our latest update, you can enjoy uninterrupted assistance from the Sequence Assistant as you seamlessly navigate through your collection of patents - say goodbye to interruptions and hello to a smoother, more efficient workflow! 
Plus, with a sleek new look, improved performance, and the new ability to instantly glance at the sequence location, let the Assistant help you to supercharge your FTO reviews.

2) Improved Sequence Extraction

In addition to its new look, the Sequence Assistant now enables you to extract sequences in any order you prefer. Say goodbye to unnecessary steps and hello to a more convenient and efficient patent review process!

3) We've also made it easier to Search & Refine in Sequence Workspaces

We now provide enhanced sequence screening options in Workspaces to empower you to efficiently pinpoint sequences of interest based on Sequence Type, Length, and even keywords!

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

Revolution Medicines initiates dosing in Phase 1/1b clinical study for RMC-9805, an orally administered, covalent, mutant-specific KRASG12D inhibitor
Latest Hotspot
3 min read
Revolution Medicines initiates dosing in Phase 1/1b clinical study for RMC-9805, an orally administered, covalent, mutant-specific KRASG12D inhibitor
26 September 2023
Revolution Medicines, Inc. has initiated Phase 1/1b trials for RMC-9805, a covalent, oral KRAS G12D inhibitor for RAS-dependent cancers and the first patient already dosed targeting KRAS G12D mutation-driven cancers.
Read →
Deep Scientific Insights on Margetuximab's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Margetuximab's R&D Progress, Mechanism of Action, and Drug Target
27 September 2023
This article summarized the latest R&D progress of Margetuximab, the Mechanism of Action for Margetuximab, and the drug target R&D trends for Margetuximab.
Read →
An In-depth Analysis of Labetalol Hydrochloride's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Labetalol Hydrochloride's R&D Progress and Mechanism of Action on Drug Target
27 September 2023
This article summarized the latest R&D progress of Labetalol Hydrochloride, the Mechanism of Action for Labetalol Hydrochloride, and the drug target R&D trends for Labetalol Hydrochloride.
Read →
Temsirolimus: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Temsirolimus: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
27 September 2023
This article summarized the latest R&D progress of Temsirolimus, the Mechanism of Action for Temsirolimus, and the drug target R&D trends for Temsirolimus.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.